Who are IgG Next Generation (BT595)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PRIVIGEN (CSL Behring), Flebogamma 5% DIF, Asceniv™, Gammaplex (5%), IgPro, IGSC 20% infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/igg-next-generation-bt595.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IgG Next Generation (BT595) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IgG Next Generation (BT595) (IgG Next Generation (BT595)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous immunoglobulin (IVIG) Immunology Biologic Live · refreshed every 30 min

Target snapshot

IgG Next Generation (BT595) (IgG Next Generation (BT595)) — Biotest. BT595 is a next-generation intravenous immunoglobulin (IVIG) product designed to provide passive immunity through polyclonal IgG antibodies with enhanced manufacturing and purification processes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IgG Next Generation (BT595) TARGET	IgG Next Generation (BT595)	Biotest	phase 3	Intravenous immunoglobulin (IVIG)
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
Flebogamma 5% DIF	Flebogamma 5% DIF	Instituto Grifols, S.A.	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors, pathogenic antigens and antibodies
Asceniv™	Asceniv™	ADMA Biologics, Inc.	marketed	Intravenous immunoglobulin (IVIG)	Polyclonal immunoglobulins (IgG)
Gammaplex (5%)	Gammaplex (5%)	Bio Products Laboratory	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors and complement system (indirect mechanism via antibody delivery)
IgPro	IgPro	CSL Behring	marketed	Intravenous immunoglobulin (IVIG)	Multiple pathogenic antigens (polyvalent)
IGSC 20% infusion	IGSC 20% infusion	Takeda	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antibodies

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IgG Next Generation (BT595) — Competitive Intelligence Brief. https://druglandscape.com/ci/igg-next-generation-bt595. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing